news and media center
See what we've been up to by viewing our press releases and featured stories below. For interview requests, please contact media@novocure.com.
View All
press releases
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide...
MoreData on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conferenc...
MoreNovocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European S...
MoreNovocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
MoreFirst Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevaciz...
MoreCombination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Severa...
MoreNovocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Glio...
MoreNovocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Qua...
MoreNovocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurolo...
MoreCNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line...
MoreCombination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Ye...
MoreCombination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent...
MoreCombination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine...
MoreNovocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with St...
MoreNovocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting...
MoreNovocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
MoreFirst Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for...
MoreNovocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblas...
MoreNovocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fiel...
MoreNovocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclita...
MoreLong-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagn...
MoreNovocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields P...
MoreNovocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st ...
MoreNovocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of th...
MoreCNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in ...
MoreNovocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academ...
Morepress kit
View our press kit to learn more about our company. For interview requests, please contact media@novocure.com.
Patient B-roll
MOA B-roll
Treatment Overview Video - Scientific
Treatment Overview Video - General Public
Novocure Annual Report
Optune Fact Sheet
Logos
Optune System infographic
Novocure media gallery
Click through our media gallery to view photos of our patients, our therapy, our employees and more.
Launch Gallery
Picture
2000 Novocure research center opens
-
about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
-
our therapy
- mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.
- delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.
- treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
-
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
- patient-forward
- news and media
- investor relations
- careers